Clera is a world leading private drug discovery and development company creating better medicines for aging related mental illnesses.
Clera is the only private drug discovery and development firm in the world with a wholly owned multiple clinical and pre-clinical drug pipeline targeting aging related mental illnesses.
Clera is targeting the massive aging related markets of depression, Parkinson’s disease, Alzheimer’s and the psychosis related to dementia, schizophrenia and Parkinson’s disease.
These combined $ 50 billion/year drug revenue markets are currently served by drugs which work poorly and have terrible side-effects.
Clera is developing better drugs with little to no side effects and currently has 4 drug programs with multiple compounds in various stages of development, including two drugs in Phase IIa human trials, to be completed in mid 2013.